Equitable Trust Co. Has $1.19 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Equitable Trust Co. cut its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 3.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,090 shares of the biopharmaceutical company’s stock after selling 800 shares during the quarter. Equitable Trust Co.’s holdings in Bristol-Myers Squibb were worth $1,193,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Soltis Investment Advisors LLC increased its position in shares of Bristol-Myers Squibb by 6.2% during the fourth quarter. Soltis Investment Advisors LLC now owns 7,843 shares of the biopharmaceutical company’s stock worth $444,000 after buying an additional 461 shares during the period. Quilter Plc increased its position in shares of Bristol-Myers Squibb by 56.6% during the fourth quarter. Quilter Plc now owns 107,818 shares of the biopharmaceutical company’s stock worth $6,098,000 after buying an additional 38,977 shares during the period. Silicon Valley Capital Partners acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $40,000. Wingate Wealth Advisors Inc. acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $146,000. Finally, Four Tree Island Advisory LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter worth $2,928,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BMY has been the subject of a number of research reports. Daiwa Capital Markets upgraded shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a report on Wednesday, November 13th. Cantor Fitzgerald raised their price target on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Morgan Stanley raised their price target on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a report on Tuesday, November 12th. Daiwa America upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 13th. Finally, Bank of America restated a “neutral” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $57.86.

Bristol-Myers Squibb Stock Down 2.4 %

BMY opened at $55.50 on Tuesday. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. The company’s 50-day moving average is $57.56 and its 200 day moving average is $53.89. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $61.10. The firm has a market capitalization of $112.55 billion, a P/E ratio of -12.56, a PEG ratio of 2.13 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.81%. Research analysts expect that Bristol-Myers Squibb will post 6.75 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were given a dividend of $0.62 per share. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.47%. The ex-dividend date was Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -56.11%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.